Masonic Cancer Center, University of Minnesota: all 285 studies
Page 3 of 3. Open to participants first (34), then studies with results posted, then the rest; newest registration first within each.
- Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel ImmunotherapiesTerminatedNCT03557749
- Ethnic/Racial Differences in Metabolism and DNA Adduct FormationWithdrawnNCT03421678
- CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid MaligCompletedNCT03383055Phase 1
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant DiseasesTerminatedNCT03367546Phase 2
- QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
- Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient InductionCompletedNCT03316456
- Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaWithdrawnNCT03297463Phase 1/2
- Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal IntCompletedNCT03213964Phase 1
- Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AMLCompletedNCT03081780Phase 1
- Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
- Glucobrassicin-Brussel Sprout Effect on D10 Phe MetabolismCompletedNCT02999399Phase 1
- Early Diagnosis Of Childhood Cerebral ALDWithdrawnNCT02948062
- Study of CD133KDEL Toxin in the Treatment for Solid TumorsWithdrawnNCT02845414Phase 1
- StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme MalignanciesWithdrawnNCT02765997Phase 2
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Investigation of Kava Effects on NNK MetabolismCompletedNCT02500472Not applicable
- MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)WithdrawnNCT02410239Phase 1
- MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant PatientsCompletedNCT02227797Phase 1
- Biomarker Feedback for Smoking CessationCompletedNCT02206971Not applicable
- Hematopoietic Stem Cell Transplant for High Risk HemoglobinopathiesTerminatedNCT02179359Not applicable
- MT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisActive, not recruitingNCT02171104Phase 2
- Treg Cells for AGVHD in Non-myeloablative UCB TransplantWithdrawnNCT02118311Phase 2
- Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerCompletedNCT02118285Phase 1
- Safety of Romiplostim (Nplate®) Following UCBTCompletedNCT02046291Phase 1
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- MIBG for Refractory Neuroblastoma and PheochromocytomaCompletedNCT01850888Not applicable
- Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute LeukemiaWithdrawnNCT01677949Phase 2
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete RemissionWithdrawnNCT01639456Phase 2
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Cancer and Mindfulness-Based Cancer Recovery After ChemotherapyCompletedNCT01601548Not applicable
- Empowering Cancer Survivors Through Information TechnologyCompletedNCT01593618Not applicable
- Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler SyndromeTerminatedNCT01572636
- High Dose Chemotherapy and Autologous Transplant for NeuroblastomaCompletedNCT01526603Not applicable
- Auto Transplant for High Risk or Relapsed Solid or CNS TumorsCompletedNCT01505569Not applicable
- Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem GliomaTerminatedNCT01400672Phase 1
- Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)CompletedNCT01385423Phase 1
- Selecting a Favorable KIR Donor in Unrelated HCT for AMLCompletedNCT01288222Not applicable
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
- Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain TumorCompletedNCT01171469Phase 1
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- Metabolism of NNK Among African AmericansCompletedNCT01158456
- Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast CancerCompletedNCT01009437Phase 1
- DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or LymphomaCompletedNCT00889408Phase 1
- Iron Overload in Patients Undergoing Donor Stem Cell TransplantCompletedNCT00888316
- Everolimus in Treating Women With Breast Cancer That Can Be Removed by SurgeryWithdrawnNCT00855114Phase 2
- Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone MetastasesWithdrawnNCT00769990Phase 1/2
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerWithdrawnNCT00748163Phase 2
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00703638Phase 1
- Total Marrow Irradiation for Refractory Acute LeukemiaCompletedNCT00686556Phase 1
- Clinical Trial of Trametes Versicolor in Women With Breast CancerCompletedNCT00680667Phase 1
- Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic LeukemiaTerminatedNCT00643240Phase 1
- Intrathecal Enzyme Replacement for Hurler SyndromeCompletedNCT00638547Phase 1
- Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal MalignanciesCompletedNCT00625092Phase 1
- MT2004-30: Tomotherapy for Solid TumorsTerminatedNCT00623077Phase 1
- Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsCompletedNCT00622674Phase 1
- Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid TumorsCompletedNCT00620295Phase 1
- Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung CancerTerminatedNCT00619021Phase 1
- Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced LeukemiaTerminatedNCT00618696Phase 1
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical CancerWithdrawnNCT00428194Phase 1
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast CancerWithdrawnNCT00373152Phase 2
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell TransplantTerminatedNCT00369291Phase 1
- Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerCompletedNCT00365287Phase 1/2
- Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLCTerminatedNCT00356941Phase 1
- PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue SarcomaCompletedNCT00346125Not applicable
- Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerCompletedNCT00290641Not applicable
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable
- Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical CancerCompletedNCT00287911Phase 1
- Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic CancerCompletedNCT00287885Phase 1
- Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00287859Phase 1
- Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant AscitesTerminatedNCT00265863Phase 2
- Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) LeukemiaCompletedNCT00167167Not applicable
- Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ TumorsCompletedNCT00095160Phase 1
- Bone Marrow Transplantation in Treating Patients With LeukemiaWithdrawnNCT00006451Phase 3
- Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseaseWithdrawnNCT00005998Phase 2
- Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast CancerTerminatedNCT00005993Phase 1
- Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple MyelomaTerminatedNCT00005987Phase 2
- Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous LeukemiaTerminatedNCT00005986Phase 2
- Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's LymphomaCompletedNCT00005985Phase 2
- Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous LeukemiaTerminatedNCT00005984Phase 2
- Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid TumorsTerminatedNCT00003926Phase 1
- Vaccination With Tetanus and KLH to Assess Immune Responses.TerminatedNCT00000105
← Masonic Cancer Center, University of Minnesota overview and focus areas